Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kerala Ayurveda's ROE % for the quarter that ended in Mar. 2026 was -279.16%. Kerala Ayurveda's PB Ratio for the quarter that ended in Mar. 2026 was 18.43.
Kerala Ayurveda's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -15.15%.
Kerala Ayurveda ROE % Adjusted to Book Value Related Terms
Kerala Ayurveda ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Kerala Ayurveda's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kerala Ayurveda ROE % Adjusted to Book Value Chart
BOM:530163 vs ZTS, UTHR: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kerala Ayurveda's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kerala Ayurveda ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kerala Ayurveda's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Kerala Ayurveda's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -15.15% mean?
Kerala Ayurveda (BOM:530163) has a ROE % Adjusted to Book Value of -15.15% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Kerala Ayurveda and its competitors.
Is Kerala Ayurveda's ROE % Adjusted to Book Value too high?
Kerala Ayurveda's current ROE % Adjusted to Book Value is -15.15%. Overall, Kerala Ayurveda has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kerala Ayurveda's ROE % Adjusted to Book Value compare to ZTS and UTHR?
Kerala Ayurveda's ROE % Adjusted to Book Value of -15.15% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Kerala Ayurveda and its competitors. Kerala Ayurveda's current ROE % Adjusted to Book Value is -15.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kerala Ayurveda stock overvalued right now?
Based on GuruFocus' analysis, Kerala Ayurveda (BOM:530163) is currently considered Possible Value Trap. The stock's GF Value™ is ₹319.48, compared to a current price of ₹169.70 — trading 46.9% below its estimated fair value. The current ROE % Adjusted to Book Value is -15.15%. Kerala Ayurveda's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Kerala Ayurveda (BOM:530163), the current ROE % Adjusted to Book Value is -15.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kerala Ayurveda (BOM:530163) Overvalued in 2026?
Based on GuruFocus' analysis, Kerala Ayurveda stock appears to be undervalued.
The current stock price of ₹169.70 is trading 46.9% below its estimated GF Value™ of ₹319.48.
GuruFocus considers Kerala Ayurveda to be Possible Value Trap.
Key valuation signals for BOM:530163:
ROE % Adjusted to Book Value: -15.15%
GF Value™: ₹319.48 vs. price of ₹169.70 (46.9% below fair value)
No single metric tells the full story. See the BOM:530163 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kerala Ayurveda Ltd is engaged in producing and selling ayurvedic products and providing healthcare services. The company offers ayurvedic medicine products for diabetes and heart health, skin and hair care, kids' health, women's care, men's care, gastro care, respiratory and allergy, general healthcare, massage oils, renal care, and joint care. It provides services through wellness clinics, resorts, hospitals, and academies. The company has only one reportable business segment, i.e., Full-spectrum Ayurvedic wellness. It generates maximum revenue from the sale of products. Geographically, the company generates maximum revenue from its business in India and also has some exposure to other markets.
47GF Score
Get the complete analysis for BOM:530163
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530163 has been successfully added to your 
